- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer-BioNTech bivalent booster for Omicron, original COVID strain gets UK nod
In each dose of the booster vaccine called "Comirnaty bivalent Original/Omicron", half of the vaccine (15 micrograms) targets the original virus strain and the other half (15 micrograms) targets Omicron (BA.1).
London: The UK health authorities have recently approved a second "bivalent" vaccine to be used as a booster vaccine to target both the Omicron and original strain of COVID-19.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the "updated booster vaccine" made by Pfizer/BioNTech was found to meet its standards of safety, quality and effectiveness.
The jab targeting two coronavirus variants has been approved for use in individuals aged 12 years and above. In each dose of the booster vaccine called "Comirnaty bivalent Original/Omicron", half of the vaccine (15 micrograms) targets the original virus strain, and the other half (15 micrograms) targets Omicron (BA.1).
"The clinical trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain," said Dr June Raine, MHRA Chief Executive.
"Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against COVID-19 variants. We have in place a comprehensive safety surveillance strategy for all UK-approved COVID-19 vaccines, and this will include the updated booster we approved today," she said.
This decision has been endorsed by the UK's Commission on Human Medicines and follows the MHRA's approval of the Spikevax bivalent Original/Omicron by Moderna last month.
"As with any medicinal product, including vaccines, it is important to continually monitor effectiveness and safety when it is deployed, and we have the relevant processes and expertise in this country to do that," said Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines.
"The Joint Committee on Vaccination and Immunisation (JCVI) will advise on how this vaccine should be offered as part of the deployment programme," he said.
The MHRA said its decision is based on data from a clinical trial which showed that a booster dose with the bivalent Pfizer/BioNTech vaccine triggers a strong immune response against both Omicron and the original strain.
Safety monitoring showed that the side effects observed were the same as those seen for the original Pfizer/BioNTech booster dose and were typically mild and self-resolving, and no new serious safety concerns were identified.
It comes as the National Health Service (NHS) announced its autumn vaccine booster rollout this weekend, with care home residents and staff set to be among the first in the world to receive the new, variant-tackling jabs from Monday.
"Our autumn booster programme kicks off from Monday, with care home residents, staff and the housebound the first to receive their jabs," said UK Health Secretary Steve Barclay.
"An autumn booster will top up the immunity of those most vulnerable to COVID ahead of the winter to help us continue to live with this virus without restrictions. Please come forward for your booster and flu vaccine when invited," he said.
As with previous campaigns, the oldest and most vulnerable will be called forward for boosters first.
"The precision and speed of the NHS COVID-19 vaccination programme allowed us to get back to a pre-pandemic way of life and doing the things that we love," said NHS Chief Executive Amanda Pritchard.
"While we know that this winter will be challenging with a likely resurgence in both COVID and flu for the first time since before the pandemic, the best way to protect yourselves and your loved ones from serious illness is to get the newly approved, next generation COVID vaccine when invited to do so, as well as your annual flu jab, to ensure you have maximum protection," she said.
Around 26 million people across England will be eligible for an autumn booster over the coming weeks, which includes over 50s, those with a weakened immune system, health and social care workers and care home residents and housebound people, in line with guidance set out by the JCVI.
booster vaccineCOVID 19omicronMedicines and Healthcare products Regulatory AgencypfizerBioNTechComirnatypfizer newsBioNTech news
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story